428
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Efficacy of golimumab for preventing large joint destruction in patients with rheumatoid arthritis as determined by the ARASHI score

, , , , &
Pages 938-945 | Received 02 Nov 2016, Accepted 05 Jan 2017, Published online: 22 Feb 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Arata Nakajima, Keiichiro Terayama, Masato Sonobe, Yasuchika Aoki, Hiroshi Takahashi, Yorikazu Akatsu, Shinji Taniguchi, Manabu Yamada, Ayako Kubota & Koichi Nakagawa. (2019) Predictive factors for radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs): Results of 3 to 4 years of follow-up. Modern Rheumatology 29:6, pages 903-909.
Read now

Articles from other publishers (3)

Hong Ki Min, Se Hee Kim, Hae-Rim Kim & Sang-Heon Lee. (2022) Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis. International Journal of Molecular Sciences 23:22, pages 13913.
Crossref
Kenjiro Fujimura, Akihisa Haraguchi, Ryuta Sakurai, Satoshi Kamura, Koji Sakuraba, Hisaaki Miyahara & Jun-ichi Fukushi. (2021) Have the radiographic characteristics of total knee arthroplasty recipients in rheumatoid arthritis changed after the induction of biologic disease modifying antirheumatic drugs?. Modern Rheumatology.
Crossref
Hiromu Ito, Furu Moritoshi, Motomu Hashimoto, Masao Tanaka & Shuichi Matsuda. (2018) Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis. Inflammation and Regeneration 38:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.